Medidata grabs software deal with Purdue Pharma

Medidata Solutions ($MDSO) has nailed down more business from a major pharma outfit. Purdue Pharma, known for making the pain drug OxyContin, has inked a multiyear deal with Medidata, expanding use of Medidata's software for clinical trials.

The news comes on the heels of upbeat financial results last week from New York-based Medidata, which increased its fourth-quarter 2012 revenue 24% to $58.6 million. Last year the company revealed deals with French pharma giant Sanofi ($SNY) and Japanese drugmaker Otsuka Pharmaceutical, while Medidata's stock price rallied up more than 150% over the past 12 months, giving the company a market cap of about $1.3 billion.

Those are big names and numbers in the growing market for clinical trials software, where Medidata CEO Tarek Sharif has steered the company to challenge its larger rival Oracle ($ORCL) and win deals while advancing a cloud computing platform that has become increasingly popular among some customers.

Purdue has opted to adopt new software from Medidata after a productive three years of using the tech company's products, including its cloud platform.

"After seeing the results we were able to achieve with Medidata's Clinical Cloud, we have enthusiastically embraced a number of new capabilities," said Charles Willmer, senior director of clinical systems, Purdue, in a statement.

- here's the release from Medidata

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.